Corvus Pharmaceuticals (CRVS)
(Delayed Data from NSDQ)
$5.91 USD
+0.30 (5.35%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.91 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
Brokerage Reports
0 items in cart
Corvus Pharmaceuticals, Inc. [CRVS]
Reports for Purchase
Showing records 21 - 40 ( 154 total )
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q21: COVID Program to Complete Enrollment by Year End 2021
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Study Advancing; CPI-818 Phase 2 Study Planned; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Year of Transformation; Lower PT to $9.50; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Reported FY2020 Results. Key COVID-19 Trial Reads Out in Late-2021
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- Takeaways from Our Covered Companies at the 33rd ROTH Annual Conference
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
You Are Invited to Our Virtual 33rd Annual ROTH Conference on March 15-17, 2021
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Dropping Coverage Due to Realignment of Analyst Resources
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Buzz Brewing for Cancer Therapy Targeting Adenosine Pathway
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
CPI-818?s Potential Broadened at ASH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Advancing CPI-006 Into Pivotal Study for COVID-19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2021 a Pivotal Year for Corvus. Top Ten Takeaways from Today''s R-D Symposium
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
SITC 2020 Abstract Preview for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts on COVID-19 Therapies in Light of Vaccine News
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T